問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


CHANGHUA CHRISTIAN HOSPITAL (在職)

Division of General Internal Medicine

Division of Endocrinology

更新時間：2023-09-19

王舒儀
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

12Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

王舒儀

CHANGHUA CHRISTIAN HOSPITAL

Division of Endocrinology

List

44Cases

2008-09-01 - 2010-12-31

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2011-12-01 - 2012-12-31

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2025-07-01 - 2030-12-31

Phase III

Active
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients with Established Atherosclerotic Cardiovascular Disease (ASCVD) or at High Risk for a First ASCVD Event

  • Condition/Disease

    Atherosclerotic Cardiovascular Disease (ASCVD)

  • Test Drug

    tablet

Participate Sites
23Sites

Recruiting23Sites

2005-06-01 - 2006-12-01

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2022-03-31 - 2024-08-30

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Not yet recruiting8Sites

2015-05-01 - 2021-05-01

Phase IV

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2024-09-01 - 2026-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2009-04-01 - 2011-12-31

Phase II

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2022-09-16 - 2026-12-31

Phase III

Completed
A Phase 3, Multicenter, Randomized, Parallel-Design, Open-Label Study to Evaluate the Efficacy and Safety of LY3209590 as a Weekly Basal Insulin Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy

  • Condition/Disease

    Type 1 Diabetes

  • Test Drug

    LY3209590/Basal Insulin - Fc (BIF)

Participate Sites
6Sites

Recruiting6Sites

2023-06-16 - 2024-05-15

Phase III

Completed
A Master Protocol to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (TRIUMPH-1)

  • Condition/Disease

    Obesity、 Overweight、 Knee Pain Chronic、 Knee Osteoarthritis、 Obstructive Sleep Apnea

  • Test Drug

    LY3437943

Participate Sites
4Sites

Recruiting4Sites

1 2 3 4 5
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB